Dr. Steven J. Mentzer is a thoracic surgeon at Brigham and Women’s Hospital and Dana-Farber Brigham Cancer Center. He is a professor of surgery at Harvard Medical School.Dr. Mentzer received his medical degree from the University of Minnesota and received his general surgical residency training at the Brigham. He completed a cardiothoracic surgery fellowship at the University of Toronto. Dr. Mentzer also completed a research fellowship at Dana-Farber Cancer Institute where he investigated the molecular mechanisms involved in the regulation of T lymphocyte function. He is board certified in surgery, cardiothoracic surgery, and surgical critical care.Dr. Mentzer’s clinical interests include diseases of the lungs and thoracic cancers, minimally invasive surgery of the lungs and esophagus, and minimally invasive surgery for esophageal cancer. Principal investigator for The Mentzer Lab, Dr. Mentzer is currently studying the adaptive processes involved in blood vessel growth (angiogenesis) and lung regeneration. Dr. Mentzer is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), ALK-Positive Non-Small Cell Lung Cancer, Gastrostomy, and Endoscopy.

Dr. Jon Wee is the Esophageal Surgery Section Chief, Director of Robotics in Thoracic Surgery, and co-Director of Minimally Invasive Thoracic Surgery at Brigham and Women’s Hospital. He is also an Associate Program Director for Thoracic Surgery and is an Assistant Professor of Surgery at Harvard Medical School.Dr. Wee received his medical degree from the Duke University School of Medicine and completed his surgical training at Brigham and Women’s Hospital. He then went on to complete his cardiothoracic surgery training at the University of Pittsburgh Medical Center. He is board certified in surgery and thoracic surgery.Dr. Wee’s clinical interest is in minimally invasive approaches to thoracic diseases. These include minimally invasive and robotic esophagectomy, lobectomy, thymectomy and mediastinal resection for thoracic malignancies.  In addition, he treats benign esophageal disease such as gastro-esophageal reflux disease, giant paraesophageal hernias, diverticulum, etc. He performs POEM procedures for achalasia as well as sympathectomy for hyperhidrosis and endoluminal therapies such as PDT, laser, and stents for palliation. His research interest is in the use of minimally invasive techniques to decrease pain, improve recovery, and improve ultimate outcomes. Dr. Wee is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Endoscopy, and Thymectomy.

Dr. Ciaran McNamee is a thoracic surgeon at Brigham and Women’s Hospital and Dana-Farber Brigham Cancer Center. He is chief of thoracic surgery at Kent Hospital and is an instructor in surgery at Harvard Medical School. Dr. McNamee received his medical degree from McGill University in Canada and completed a surgery residency at University of Alberta Hospital as well as cardiothoracic surgery residencies at Broadgreen Hospital and Royal Devon and Exeter Hospital. He completed a clinical fellowship in thoracic surgery at the University of Manitoba and a research fellowship in thoracic surgery at the University of Alberta. Board certified in surgery and thoracic surgery, Dr. McNamee holds a Fellowship of the Royal College of Surgeons (FRCS). Dr. McNamee's clinical interests include lung cancer, lung cancer screening and esophageal cancer. His research focuses on mutational changes in lung cancer, regional outcome analysis and telemedicine. Dr. McNamee has been listed as one of America’s Top Doctors by Castle Connolly. Dr. Mcnamee is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Lung Adenocarcinoma, Gastrostomy, and Advanced Bronchoscopy.

Dr. Wain joined the Brigham in February 2023 as a Surgeon, and Associate Chief of Quality and Safety, both for the Thoracic Surgery Department. Before joining the Brigham, Dr. Wain was the chief of the Division of Thoracic Surgery and the vice chairman of the Department of Surgery at St. Elizabeth’s Medical Center He’s a member of various societies, including the American Thoracic Society, the American College of Chest Physicians, the Society of Thoracic Surgeons and the American Association for Thoracic Surgery. Dr. Wain received his undergraduate degree from Pennsylvania State University and his medical degree from Jefferson Medical College. He completed residency training in surgery at Massachusetts General Hospital. After a surgical research fellowship at the City of Hope National Medical Center, he completed a fellowship in cardiothoracic surgery at Massachusetts General Hospital and Toronto General Hospital. He is certified by the American Board of Surgery and the American Board of Thoracic Surgery. Dr. Wain is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Osteotomy.

Dr. Daniel C. Daniel Wiener is a thoracic surgeon at Brigham and Women's Hospital and an Assistant Professor of Surgery at Harvard Medical School. After graduating with honors from Columbia University, College of Physicians and Surgeons, he completed his surgical training at Dartmouth Hitchcock Medical Center. With additional training as research fellow in tumor immunology at the Dana Farber Cancer Institute, he then pursued his interest in thoracic surgery as a resident at Brigham and Women's Hospital. He is board certified in general surgery and thoracic surgery. Dr. Wiener is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Hiatal Hernia, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, Endoscopy, and Thymectomy.

Dr. Hisashi Tsukada is a thoracic surgeon at Brigham and Women’s Hospital.  He is also an assistant professor in surgery at Harvard Medical School. He received his medical degree and a PhD in medicine from St. Marianna University School of Medicine (Kawasaki, Japan). He then completed a residency in surgery at Mitsui Memorial Hospital (Tokyo). His fellowships include thoracic surgery at St. Marianna University Hospital, thoracic surgery research at Beth Israel Deaconess Medical Center and interventional pulmonology at St. Elizabeth’s Medical Center.   Dr. Tsukada specializes in Interventional Pulmonology and his clinical interests concentrate on aligning his research investigations to disease processes he has observed in patients as a practicing thoracic surgeon for more than ten years in Japan. Dr. Tsukada started his service at Brigham and Women’s Hospital in October 2014. He has expanded the Interventional Pulmonology procedures up to 1,000 cases per year in 2023. Dr. Tsukada is research focuses on developing an artificial trachea for in vivo implantation and airway tissue regeneration. He has authored 30 peer-reviewed publications. Dr. Tsukada is fluent in Japanese. Dr. Tsukada is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Lymphofollicular Hyperplasia, Mesothelioma, Advanced Bronchoscopy, and Endoscopy.

Katherine Krajewski is a Radiologist in Boston, Massachusetts. Dr. Krajewski is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Renal Cell Carcinoma (RCC), ALK-Positive Non-Small Cell Lung Cancer, Cholangiocarcinoma (Bile Duct Cancer), and WT1-Related Wilms Tumor Syndromes.

Dr. Raymond Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation, Thoracic Radiation Oncology Disease Site Leader, and Director of Patient Safety/Quality in the Department of Radiation Oncology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute.Dr. Mak received his undergraduate degree from Cornell University and medical degree from Harvard Medical School, trained at the Harvard Radiation Oncology Residency Program, and is board certified in Radiation Oncology.Dr. Mak has over 10 years of experience in radiation treatment of thoracic malignancies including lung cancer, mesothelioma, and thymomas, and in the clinical application of advanced radiation therapy techniques including stereotactic body radiation therapy.  He has applied stereotactic body radiation therapy for novel indications including the treatment of cardiac arrhythmias. He led the implementation of MR-guided radiation therapy and adaptive radiation therapy program at BWH/DFCI in 2019 and has expertise in these innovative new treatment approaches. His research interests focus on developing genomic and imaging biomarkers to predict radiation therapy response and toxicity for lung cancer patients, and applying artificial intelligence techniques to automate radiation therapy planning and improve patient care. He has expertise in developing new methods to reduce the risk of cardiac and pulmonary toxicity for patients receiving radiation therapy. Dr. Mak is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

David Kozono is a Radiation Oncologist in Boston, Massachusetts. Dr. Kozono is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Deepa Rangachari is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Rangachari is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Thymectomy.

Michael Kent is a Thoracic Surgeon and a General Surgeon in Boston, Massachusetts. Dr. Kent is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Endoscopy, and Gastrostomy.

Daniel Costa is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Costa is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Salomao Faintuch is a Radiologist in Boston, Massachusetts. Dr. Faintuch is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Fibrolamellar Carcinoma, ALK-Positive Non-Small Cell Lung Cancer, End-Stage Renal Disease (ESRD), Embolectomy, and Liver Embolization.

Mihir Parikh is an Internal Medicine provider in Boston, Massachusetts. Dr. Parikh has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Tracheobronchomalacia, Acquired Tracheomalacia, Pleurisy, Gastrostomy, and Advanced Bronchoscopy.

Sidharta Gangadharan is a Thoracic Surgeon in Boston, Massachusetts. Dr. Gangadharan is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Tracheobronchomalacia, Acquired Tracheomalacia, Lung Nodules, Endoscopy, and Gastrectomy.

Mark Hammer is a Radiologist in Boston, Massachusetts. Dr. Hammer has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Nodules, ALK-Positive Non-Small Cell Lung Cancer, Pleural Effusion, and Pleurisy.

Raymond Huang is a Neuroradiologist in Boston, Massachusetts. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Pediatric Low-Grade Glioma (pLGG), Subarachnoid Hemorrhage, and Radiation Induced Meningioma.

Michael Rabin is an Oncologist in Boston, Massachusetts. Dr. Rabin is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Jacob Sands is an Oncologist in Boston, Massachusetts. Dr. Sands is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Christopher Lathan is an Oncologist in Boston, Massachusetts. Dr. Lathan is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.